All right. Good morning, everyone, and welcome to the OKYO Pharma presentation. OKYO is an ophthalmology company developing a treatment for neuropathic pain, and I am happy to have Robert Dempsey, CEO of OKYO, here to present the company. Robert, take it away. We will for Q&A at the end.
Thank you very much, and thank you for the Stifel team for the opportunity to present. My name is Robert Dempsey, and I am the CEO of OKYO Pharma. At OKYO, we are focused on addressing unmet needs in corneal and anterior segment diseases of the eye. We believe we have a differentiated therapeutic approach targeting a potential blockbuster-scale market opportunity of which there are no FDA-approved programs. We are a publicly traded company. Big news, on the cusp of the American Academy of Ophthalmology in early October, we announced the first subjects were enrolled in our pivotal phase III trial, referred to as the NEPTUNE trial, for patients with neuropathic corneal pain. What I would like to do is set the stage where we are today. We believe at OKYO, we are pioneering a new ocular therapeutic market with urcosimod.
So, urcosimod is a novel non-opioid preservative-free eye drop with a dual pain-relieving as well as anti-inflammatory activity for patients with neuropathic corneal pain. Let us set the stage for patients with neuropathic corneal pain. First and foremost, this is a severe debilitating condition in which there is significant impact on patients' quality of life, of which there is no FDA-approved program. These patients commonly experience pain, photophobia, and unfortunately, a constant burning and foreign body sensation, and as mentioned, significantly impacting the patient's quality of life. Our approach is a novel mode of action with urcosimod that targets the ChemR23 receptor on the corneal surface, which is a differentiated dual mechanism that modulates both neuropathic pain signaling as well as immune-mediated inflammation. Why are we so excited?
Under the direction of Dr. Pedram Hamrah at Tufts Medical Center in Boston, he conducted a proof-of-concept study in which urcosimod demonstrated a clinically meaningful reduction in pain, of which we saw a 5.5 improvement utilizing the 10-point VAS score. The VAS score is a visual analog scale that has a scale of 0, no pain, to 10, the most excruciating pain that one can imagine. What we saw is that 75% of patients achieved a greater than 80% improvement in their pain. As I like to say, the good news does not stop there in the symptom relief of these patients. We also saw a strong effect on the patient's nerves, on the nerve plexus, in which we signaled the potential for corneal nerve restoration. As you can imagine, the patients had a significant relief in their symptom of pain.
We saw a strong signal in the sign of nerve regeneration, while we also saw an improvement in these patients' quality of life, which we believe is an important measure of the impact of this drug. From a safety perspective, the drug is well tolerated, and we didn't see any serious adverse events in any of the clinical trials that we've done. We're also very excited about the development plan moving forward. As mentioned, we have activated our phase III NEPTUNE trial, and this study will enroll approximately 111 subjects in a 2:1 randomization schedule compared to placebo. As you can imagine, going into phase III, we had to develop our commercial-grade study lot, which we've done, and we expect to have top-line data now that we've initiated the study in the back half of next year.
Our engagements with the agency have gone very well, in which we have the first and only IND that's been awarded in this space, as well as Fast Track designation. In discussions with Dr. Bill Boyd, Director of the agency ophthalmology division, we have confirmed our primary endpoint being the VAS score. We have confirmed our sample size being approximately 111 subjects in this trial, and the fact that this is the potential pivotal trial for FDA approval. The team has worked extensively on our intellectual property, and we have IP protection through at least 2039. I'm also very excited about the commercial research that we've done. We believe there's a robust market potential for this opportunity, and as you can see here, potential blockbuster-scale market opportunity.
The ongoing market research, as I like to say, has jumped off the page, in which the eye care professionals and payers are signaling the opportunity for a premium pricing strategy. We'll have more information on that in a few moments. Since joining in January, we've engaged institutional investors. We had a raise of approximately $22 million all in. I'll call your attention to the institutional investors. Bringing in this group of institutional investors, both during the raise as well as in the open market, is a strong signal of a validation. Why? Because these are ophthalmology investors. They have over 30 positions in the ophthalmology space. With the raise that we did, we are well capitalized through the clinical study well into 2027. From a development pipeline perspective, obviously we're very excited to be in phase III.
Our Chief Medical Officer, our Chief Development Officer, and I are looking at other opportunities to de-risk this opportunity. We believe, based on the mode of action of urcosimod, there are opportunities in rare corneal diseases. We're in the process of exploring these opportunities to help diversify our portfolio. What I'd like to do now is take a look at this market, the disease background, the patient journey, as well as the commercial opportunity. First and foremost, this condition, neuropathic corneal pain, is significantly under-researched with a substantial impact on the patient's quality of life. Unfortunately, it's an ill-defined disease that presents with pain, oftentimes not only in the eye, but in the head and the face. As mentioned, it's a debilitating pain.
As you can imagine, the highest concentration of nerves are on your corneal surface, and when they are inflamed and when they are damaged, there is a significant impact on patients' quality of life and, unfortunately, their ability to work. From a standpoint of medical education, it is a challenge to diagnose for the ophthalmic community. Hence, as we have entered phase III, we are engaging both sides of the ophthalmology and optometry, as I like to say, both sides of the aisle, to help from a medical educational perspective. As mentioned, it is an underserved market of which there is no FDA-approved program. The treatments, so we have done a lot of research from this perspective, and unfortunately, because there is no FDA-approved program, physicians are treating patients with non-steroidals, with steroids, with serum tears, and unfortunately, in severe cases, they are using oral medications.
I can assure you, spending 30 years in the ophthalmology space, ophthalmologists do not like using pain medications and oral medications to treat these patients. Let us kind of look at the patient journey. I think it is very important to point out that the initial presentation is oftentimes with a primary care physician, and obviously they refer them quickly to an eye care specialist, whether it is an optometrist and/or ophthalmologist. One of the things we have learned in our market research, it is difficult for the, quote unquote, general eye care physicians to diagnose these patients, ultimately leading these patients to a more specialized ocular healthcare professional at an academic center in which they can do more extensive evaluation, the proparacaine challenge, and in some cases, utilizing the confocal microscope to look at the integrity of the nerves to see if they are actually damaged and dysfunctional.
Bottom line, patients are frustrated because of the misdiagnosis and oftentimes going from physician to physician. As you can imagine, the physicians are also frustrated with the lack of knowledge and diagnostic tools to make this actual diagnosis. Bottom line, delaying this diagnosis results in patients progressing to centralized pain, which could be much more difficult for these physicians to treat these patients. As mentioned, very excited about our commercial work. Our commercial assessment and pricing strategy is on track. From a market characterization perspective, no FDA-approved program, no ICD-10 code. We have done extensive work from an epidemiology perspective to understand this market, working with two of the best companies in the space, Komodo and Verana, and working with the IRIS Registry to get a better understanding of the market potential and market size.
We should have that data done, excuse me, completed by the end of the year. From a commercial perspective, we have completed the target product profile, and that is in the field literally as we speak. Based on some of the early reports from the eye care professionals, we see a strong endorsement of this target product profile. In addition, we have also met with payers, and what the payers are signaling is the opportunity for a premium pricing strategy. Obviously, there is an important comp in this space with the great work our friends have done at Dompé with the drug OXERVATE for a similar condition of the corneal surface neurotrophic keratitis. We believe based on the comps, based on the target product profile, and based on the receptivity, it has been very strong to date. Why is that?
Well, first of all, severe debilitating condition in which there's significant impact on patients' quality of life, no FDA-approved program, and the fact that we have a novel first-in-class opportunity here, and a product that targets both inflammation and pain. Last but not least, as you start on the patient journey, prescribed by cornea specialists. We believe all this comes to the conclusion that there's a premium pricing potential and the potential for profitable access per treatment cycle. As mentioned, ophthalmologists, and in some cases optometrists, do not like using oral medications. When we're doing our analysis, one of the oral medications that's used most often is gabapentin. Unfortunately, it's prescribed off-label. Multiple states have restricted the use of this program, and there's a growing concern around dependence and misuse of using gabapentin to treat patients with neuropathic corneal pain.
Hence, there's a lot of anxiety and concern and need for a program that can treat these patients. Now what I'd like to do is transition into the mode of action as well as the clinical rationale. First and foremost, urcosimod. It's a lipidated peptide designed to selectively target the ChemR23 receptor, which is a key regulator of ocular pain and inflammation. Urcosimod has demonstrated both in animal models as well as humans, both analgesia as well as anti-inflammatory activity. The ChemR23 receptor is a key regulator of neuropathic pain signaling as well as ocular inflammation. I'll call your attention to the right-hand side of the screen, which gives a nice graphical representation of the molecule. Bottom line, this is a first-in-class chemerin receptor agonist that offers a dual mechanism of action. Transitioning to how we got to neuropathic corneal pain.
The original work was done in dry eye disease, and having spent some time in the space, I know it very well. It's crowded and can be somewhat difficult to differentiate programs. As the company was doing an analysis of the data, they saw that urcosimod demonstrated a significant relief in pain in this dry eye study. What's interesting is this study was not enriched to show a difference in pain, yet to do that in this study was a very important opportunity for the company to pivot into neuropathic corneal pain. Plus, we conducted a mouse model that looked at the effect of urcosimod compared to gabapentin. To set this up, the animals had a nerve ligation model to create neuropathic corneal pain in the mouse, and they applied urcosimod to the corneal surface as well as IP delivery of gabapentin.
As you can see here, to be as effective or almost as effective as gabapentin gave the company a lot of confidence to move forward. We saw effect as soon as day three, day eight, as well as day 10. That led the company to the pivot, which obviously I'm very excited to talk to you about today, in neuropathic corneal pain. So, we conducted a phase II proof-of-concept study under the direction of Pedram Hamrah in Boston, Massachusetts, in which the primary endpoint was the Visual Analogue Scale, and they looked at numerous secondary as well as exploratory endpoints. What we found in this clinical trial is that we demonstrated a clinically meaningful drug effect. This was a randomized, double-masked, placebo-controlled study in patients with neuropathic corneal pain.
After 12 weeks of treatment, as previously mentioned, 75% of per-protocol patients received a greater than 80% reduction in NCP as measured by the Visual Analogue Scale. The good news doesn't stop there. We also demonstrated a steep decline of pain in just four weeks, representing a potential quick onset of action. As an analysis that we conducted, we found that higher baseline pain severity is associated with a greater treatment effect of drug, and you can clearly see that, and I'll call your attention to the graph on the bottom right. In this patient population, enriched in moderate to severe pain, showed a greater reduction and almost a four-point delta at the conclusion of the study of urcosimod compared to placebo, giving a lot of confidence to move this program forward. I always like to say the good news doesn't stop there.
As mentioned, urcosimod signaled the potential for disease-modifying activity in which we saw a favorable impact on corneal nerve health, demonstrating the potential for corneal nerve restoration, of which we saw an increase in the total nerve fiber count as well as an increase in the total nerve fiber length. That gives us a lot of confidence of anatomic improvement, supporting the concept of nerve restoration and the potential for first-in-class opportunity here with urcosimod. Now the big news is the FDA has approved our phase III study design, referred to the study as the NEPTUNE study. Let's take a deeper dive at it. This is a phase III randomized double-masked placebo-controlled study in which we're planning to enroll approximately 111 adult patients. There'll be two treatment arms in a 2:1 randomization schedule. Why 2:1?
We want to have the highest probability as we're recruiting patients to have them on active compared to placebo. The treatment duration will be 12 weeks, in which there'll be a follow-up one month following stoppage of the drug, and there'll be five scheduled visits. Right now, as we speak, we're looking at approximately 13 centers, eight in the U.S. and five in Europe. We have enrolled our first subjects at a center, the Toyos Clinic in Tennessee, and we have multiple academic centers scheduled to come on over the next couple weeks in the U.S. We anticipate Europe being activated by the back half of, excuse me, by the end of the year, as well as going into the first quarter of next year.
As mentioned, the primary endpoint has been endorsed by the FDA, and that will be ocular pain reduction utilizing the 10-point VAS score. The FDA has agreed on a two or greater point improvement versus placebo as being clinically meaningful as well as label-enabling. As you can imagine, we're also going to be looking at numerous secondary and exploratory endpoints, including quality of life measures, as well as the effect of the drug on the corneal nerves utilizing the confocal microscope, which we believe, based on the market research we're doing, could be a significant game-changer in supporting a premium price reimbursement strategy. I'll call your attention to the numerous value inflection points that we're focused on.
Big box to check is initiating the NEPTUNE trial in the U.S., followed closely by the end of the year, if not into the early part of next year, activating sites in Europe. Right now in Europe, we're planning sites in Italy, Spain, France, as well as next week, I'll be in London exploring an opportunity at Moorfields for another center. We want to have enrollment completed by the midpoint of next year. We want to have top-line data by the back half of next year, and then obviously plan to have an engagement with the FDA to talk about next steps. As mentioned, based on our capital raise that we did earlier this year, we are well-capitalized for our phase III program. The team and I are laser-focused on execution, both on near-term clinical as well as commercial milestones.
As we close out the year, we've had two very successful engagements with the FDA, a type C and a type D meeting. We've initiated the NEPTUNE trial, as we indicated, and obviously we announced prior to the American Academy of Ophthalmology in early October. Now the team is laser-focused. We want to bring EU on board because having the opportunity to have five sites there will help tremendously from a recruitment perspective. We are really close to finalizing our epidemiology and market size work, will help us to calculate the market opportunity. Our market research, again, I have already received top-line data, and we want to have this closed out by the end of this year into the beginning of next.
We want to complete enrollment by the midpoint of next year, flip the card over, and have the top-line data for our phase III trial in the back half of next year. Then obviously, the team and I will be preparing towards the end of next year, in the beginning of 2028, for an FDA meeting. At OKYO, we are fast-tracking a potential therapy for neuropathic corneal pain patients, of which there is a significant high unmet need. From a clinical evidence perspective, our phase II proof of concept clearly demonstrated a promising drug effect, of which we saw a 5.5 improvement on that 10-point VAS score, of which 75% of patients achieved a greater than 80% improvement in their pain. From an unmet need perspective, it's a blank slate.
There's no FDA-approved programs, and as mentioned from our market research perspective, there's an opportunity for first-line therapy with positive reimbursement. Again, the team and I are clearly focused on our critical milestones. We've gained alignment with the FDA with two FDA meetings earlier this year, Type C and Type D. We have initiated our NEPTUNE trial, as mentioned, and we want to have this study be full enrolled by the midpoint of next year and have top-line data by the back half of next year. With that, thank you very much. Thank you for the Stifel team for the opportunity to present, and I'll pause there, see if you have any questions.
Sure. Of course, I do have a couple questions. Just wanted to hear a little bit more about the clinical history. You mentioned that you were studying urcosimod in dry eye disease.
Yes.
But then you identified this impact on corneal pain. How much more clinical work had been done on the corneal pain aspect of it? Was it just pulled from the dry eye disease, or was that phase II-A very specific to corneal pain?
Yeah, so I think it's twofold, and it's a great question about how we identified the opportunity in neuropathic corneal pain. First and foremost, it was the dry eye study. So you have a baseline of patients that have various degrees of pain. As part of the analysis, they hit a statistical significance in that dry eye study, gave us confidence that, first of all, dry eye is a competitive market, having spent a lot of time there, and hitting neuropathic corneal pain was very interesting. Plus the animal work that we did in the mouse model. A little bit more on that mouse model. That was developed by our Chief Medical Officer when he was at his former company. So he was very aware of that.
And so looking at that mouse model, it was in collaboration with Tufts, again, with Dr. Hamrah, in which when they had that data, coupled with the dry eye data and some of the market dynamics in dry eye and the market opportunity in NCP, that's what helped cause the company to do the pivot.
Okay. Did you have to do any bridging studies from that proof of concept into the phase III, or it went Fast Tracked right to phase III?
Fast Tracked right to phase III. We presented this concept to the agency through our Type C and our Type D meeting, and I think the Director, Dr. Boyd, clearly saw this is significant unmet need. When we talked to him about some of the challenges the physicians are having with these patients, unfortunately, some of these patients can have such extensive pain that they are suicidal, that the agency agreed with our approach to go right into phase III.
I saw you are going to have 100 and, I think, 11 patients in the phase III?
111, that is correct. Yeah.
What are some of the safety requirements that the FDA is asking of you? Do you need a deeper database, or are you going to need additional studies on top of that phase III?
We will need a safety database study done. As you know, to have approximately 300 subjects exposed to your active compounds. In addition to the work we're doing in our phase III trial, we will at some point have to complete a safety study as part of our enrollment submission to the agency.
Are you going to do any of that in parallel, or you're just waiting for the readout?
Yet to be determined.
Okay.
It's a great question.
Is that a funding question?
It might be a funding question, but obviously we're going to be opportunistic about that opportunity.
Okay. I know you mentioned greater than two points on the VAS score is clinically meaningful.
Yes.
Can you tell us how the study is powered? I mean, you did 5.5 points in the phase II-A.
Yes. So at the end of the phase II-A, we saw approximately a four-point delta between active and placebo. For this study, we need approximately a two-point delta. So from that perspective, we think we're in a very good position from a standpoint of hitting the statistical significance value that's required.
How variable is the patient population in terms of the waxing and waning?
Yeah, it's a great question. So this is a pain study, and as you can imagine, looking at the effect of that phase II study, we definitely saw a placebo effect at four weeks. But what's interesting, if you look at the graph, we saw a continued downward slope of the patients on active, and after four weeks, it definitely was a separation with placebo patients heading back towards baseline. So we would expect that in a placebo effect, but to help minimize the effect of placebo effect, what we're doing is trying to enrich the population. So a pain score of five or greater, the presence of microneuromas. So each site has to have a confocal microscope.
The confocal microscope will be used to identify patients that have these microneuromas, and the patients would have to undergo what is called a proparacaine challenge, which is an anesthetic drop applied to the ocular surface, and that will help differentiate between centralized pain and neuropathic pain. We believe, based on this inclusion criteria, we are enriching the population as great as possible to show the delta that is going to be required.
Okay, great. Can you just cover exactly how broad the prevalence is of this condition?
Yeah, it is a great question.
How easy they are to identify?
Yeah. That is one of the first things I started working on.
To get to the point when I started in January, we got the funding in February. Almost immediately thereafter, we kicked off this epidemiology study. As mentioned, working with both Verana and the IRIS Registry, which is associated with the Academy of Ophthalmology, we have done a language-based analysis, language-based model, to pull out certain words used in the diagnosis to identify these patients. Where we are right now is it is probably not an Orphan indication, so we probably at this time would not be applying for Orphan Drug designation. However, we do believe it is in that somewhere between 200 and probably significantly less than a million patients. Again, that is a ballpark estimate right now. I have to wait until I get the final epidemiology work.
Once we have that, we will then put it into the model of receptivity that we are seeing from the eye care professionals and really build out how we can model the financials.
Okay. Is there any opportunity to get Breakthrough designation for this, or do you need Orphan status?
The short answer is yes.
Okay.
That's a significant opportunity, and we will be evaluating that shortly. What's interesting is our discussions with the agency have gone very well. Dr. Boyd was very familiar with this condition and provided us some great feedback. Obviously, we're going to evaluate the Breakthrough designation and the opportunity there.
Okay. I guess last question, most important, cash position. What are you positioned to be able to complete here and-
Yeah. So, wonderful question about cash position. So we're very comfortable with the raise that we did, all in $22 million with the greenshoe. That'll allow us to get through to top-line data readout. Obviously, we'll be opportunistic, looking at the opportunities to bring in more cash to help expedite the opportunity. Fortunately, from a medical affairs, medical education perspective, we've also initiated those activities. Coming on the heels of the Academy of Ophthalmology and Academy of Optometry, we're engaging some of the top KOLs to help get the word out there about neuropathic corneal pain. And based on the receptivity we've had from the ophthalmic community, they're very excited about advancing this program.
Okay. Then, just one more clinical question. Once the patients stopped treatment, was there rebound? What kind of durability did those patients say?
Yeah, it's a great question about durability. So at the end of the proof of concept study, patients were observed for an additional month, and we definitely saw an effect last at least up to that point. Now, obviously, after four months, the patients, we didn't evaluate them at that point. What we're anticipating is a potential treatment cycle of one, maybe two treatment cycles every year. With pain conditions, especially pain on the cornea, based on my previous work in dry eye, patients will be very focused on taking the medication when they're symptomatic. When their eyes start to feel better, what we've seen in dry eye and other conditions of the cornea, the patients will stop. So we anticipate that the patients will be utilizing a treatment cycle, again, of once or twice per year.
I know we're almost out of time, but we are out of time. But when you have corneal nerve restoration,
Yes.
Is there a possibility that this could be curative?
I don't know. I'd have to wait until we get the data on that. But we definitely saw a strong signal of the nerve plexus, the integrity of the nerves being improved, and the fact that you can study that with the confocal microscope gives us a lot of confidence, and hence why that's an exploratory endpoint moving forward.
Okay. Got it. Thank you. We're definitely out of time.
Sounds good. Thank you very much.